The Medicines Company announced the FDA has approved Raplixa (fibrin sealant) and the Ralpixa Spray device to provide adjunctive hemostasis...
The European Commission has granted marketing authorization for Raplixa (sealant powder), from The Medicines Co., for use as a haemostatic...
The Medicines Company announced that it has entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt will...
The Medicines Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...